Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults
| Autor: | Mauricio Romero-Gonzalez, Gregory J. DiGirolamo, David A. Smelson, Gerardo Gonzalez, Monika E. Kolodziej, Douglas M. Ziedonis |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Adolescent Narcotic Antagonists media_common.quotation_subject Toxicology Placebo Article Young Adult Double-Blind Method Memantine Recurrence Naloxone Opiate Substitution Treatment Humans Medicine Pharmacology (medical) media_common Pharmacology Dose-Response Relationship Drug business.industry Abstinence Opioid-Related Disorders Discontinuation Psychiatry and Mental health Anesthesia Female Buprenorphine Naloxone Drug Combination business medicine.drug Buprenorphine Methadone |
| Zdroj: | Drug and Alcohol Dependence. 156:243-253 |
| ISSN: | 0376-8716 |
| DOI: | 10.1016/j.drugalcdep.2015.09.020 |
| Popis: | Opioid use disorders are considered a serious public health problem among young adults. Current treatment is limited to long-term opioid substitution therapy, with high relapse rates after discontinuation. This study evaluated the co-administration of memantine to brief buprenorphine pharmacotherapy as a treatment alternative.13-week double-blind placebo-controlled trial evaluating 80 young adult opioid dependent participants treated with buprenorphine/naloxone 16-4mg/day and randomized to memantine (15mg or 30mg) or placebo. Primary outcomes were a change in the weekly mean proportion of opioid use, and cumulative abstinence rates after rapid buprenorphine discontinuation on week 9.Treatment retention was not significantly different between groups. The memantine 30mg group was significantly less likely to relapse and to use opioids after buprenorphine discontinuation. Among participants abstinent on week 8, those in the memantine 30mg group (81.9%) were significantly less likely to relapse after buprenorphine was discontinued compared to the placebo group (30%) (p0.025). Also, the memantine 30mg group had significantly reduced opioid use (mean=0, SEM±0.00) compared to the placebo group (mean=0.33, SEM±0.35; p0.004) during the last 2 weeks of study participation.Memantine 30mg significantly improved short-term treatment with buprenorphine/naloxone for opioid dependent young adults by reducing relapse and opioid use after buprenorphine discontinuation. Combined short-term treatment with buprenorphine/naloxone may be an effective alternative treatment to long-term methadone or buprenorphine maintenance in young adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect